US Stock MarketDetailed Quotes

DNLI Denali Therapeutics

Watchlist
  • 14.160
  • +0.200+1.43%
Close May 15 16:00 ET
  • 14.160
  • 0.0000.00%
Post 17:04 ET
2.06BMarket Cap-5.30P/E (TTM)

Denali Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
Total revenue
0
0
0
0
0
0
204.74%330.53M
0
-64.40%1.27M
460.45%294.12M
Operating revenue
--0
--0
--0
--0
--0
--0
214.60%330.53M
--0
588.59%1.27M
460.45%294.12M
Cost of revenue
Gross profit
Operating expense
10.08%145.58M
-4.81%501.88M
-2.06%129.85M
7.06%123.19M
-5.70%116.59M
-15.20%132.25M
17.37%527.23M
14.65%132.57M
3.62%115.06M
8.56%123.64M
Selling and administrative expenses
16.31%29.35M
2.02%105.44M
21.36%30.06M
-1.48%24.95M
-3.55%25.19M
-7.02%25.24M
14.23%103.35M
5.33%24.77M
8.88%25.33M
23.45%26.12M
-General and administrative expense
16.31%29.35M
2.02%105.44M
21.36%30.06M
-1.48%24.95M
-3.55%25.19M
-7.02%25.24M
14.23%103.35M
5.33%24.77M
8.88%25.33M
23.45%26.12M
Research and development costs
8.61%116.23M
-6.47%396.44M
-7.44%99.79M
9.47%98.24M
-6.28%91.4M
-16.92%107.02M
18.16%423.88M
17.04%107.8M
2.22%89.74M
5.16%97.52M
Operating profit
-10.08%-145.58M
-155.15%-501.88M
2.06%-129.85M
-8.25%-123.19M
-168.39%-116.59M
-9.47%-132.25M
42.27%-196.7M
-25.85%-132.57M
-5.87%-113.8M
377.59%170.48M
Net non-operating interest income expense
-20.76%12.61M
25.49%64.64M
15.48%15.16M
10.75%16M
36.18%17.57M
44.22%15.91M
248.62%51.51M
97.13%13.13M
244.92%14.44M
386.98%12.9M
Non-operating interest income
-20.76%12.61M
25.49%64.64M
15.48%15.16M
10.75%16M
36.18%17.57M
44.22%15.91M
248.62%51.51M
--13.13M
--14.44M
386.98%12.9M
Other net income (expense)
14.54M
0
14.54M
Special income (charges)
--0
--14.54M
--0
--0
--0
--14.54M
--0
--0
--0
--0
-Gain on sale of business
--0
--14.54M
--0
--0
--0
--14.54M
--0
--0
--0
--0
Income before tax
-30.62%-132.97M
-191.13%-422.71M
3.98%-114.69M
-7.89%-107.19M
-154.00%-99.03M
7.27%-101.8M
55.46%-145.19M
-21.04%-119.44M
3.82%-99.35M
412.05%183.38M
Income tax
126.67%68K
42.86%30K
Net income
-30.62%-132.97M
-191.12%-422.77M
3.95%-114.75M
-7.89%-107.19M
-154.00%-99.03M
7.27%-101.8M
55.45%-145.22M
-21.07%-119.47M
3.82%-99.35M
411.91%183.38M
Net income continuous Operations
-30.62%-132.97M
-191.12%-422.77M
3.95%-114.75M
-7.89%-107.19M
-154.00%-99.03M
7.27%-101.8M
55.45%-145.22M
-21.07%-119.47M
3.82%-99.35M
411.91%183.38M
Minority interest income
Net income attributable to the parent company
-30.62%-132.97M
-191.12%-422.77M
3.95%-114.75M
-7.89%-107.19M
-154.00%-99.03M
7.27%-101.8M
55.45%-145.22M
-21.07%-119.47M
3.82%-99.35M
411.91%183.38M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-30.62%-132.97M
-191.12%-422.77M
3.95%-114.75M
-7.89%-107.19M
-154.00%-99.03M
7.27%-101.8M
55.45%-145.22M
-21.07%-119.47M
3.82%-99.35M
411.91%183.38M
Basic earnings per share
-14.71%-0.78
-142.45%-2.57
22.09%-0.67
12.50%-0.63
-144.03%-0.59
15.00%-0.68
59.23%-1.06
-14.67%-0.86
14.29%-0.72
379.17%1.34
Diluted earnings per share
-14.71%-0.78
-142.45%-2.57
22.09%-0.67
12.50%-0.63
-145.38%-0.59
15.00%-0.68
59.23%-1.06
-14.67%-0.86
14.29%-0.72
370.83%1.3
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023
Total revenue 000000204.74%330.53M0-64.40%1.27M460.45%294.12M
Operating revenue --0--0--0--0--0--0214.60%330.53M--0588.59%1.27M460.45%294.12M
Cost of revenue
Gross profit
Operating expense 10.08%145.58M-4.81%501.88M-2.06%129.85M7.06%123.19M-5.70%116.59M-15.20%132.25M17.37%527.23M14.65%132.57M3.62%115.06M8.56%123.64M
Selling and administrative expenses 16.31%29.35M2.02%105.44M21.36%30.06M-1.48%24.95M-3.55%25.19M-7.02%25.24M14.23%103.35M5.33%24.77M8.88%25.33M23.45%26.12M
-General and administrative expense 16.31%29.35M2.02%105.44M21.36%30.06M-1.48%24.95M-3.55%25.19M-7.02%25.24M14.23%103.35M5.33%24.77M8.88%25.33M23.45%26.12M
Research and development costs 8.61%116.23M-6.47%396.44M-7.44%99.79M9.47%98.24M-6.28%91.4M-16.92%107.02M18.16%423.88M17.04%107.8M2.22%89.74M5.16%97.52M
Operating profit -10.08%-145.58M-155.15%-501.88M2.06%-129.85M-8.25%-123.19M-168.39%-116.59M-9.47%-132.25M42.27%-196.7M-25.85%-132.57M-5.87%-113.8M377.59%170.48M
Net non-operating interest income expense -20.76%12.61M25.49%64.64M15.48%15.16M10.75%16M36.18%17.57M44.22%15.91M248.62%51.51M97.13%13.13M244.92%14.44M386.98%12.9M
Non-operating interest income -20.76%12.61M25.49%64.64M15.48%15.16M10.75%16M36.18%17.57M44.22%15.91M248.62%51.51M--13.13M--14.44M386.98%12.9M
Other net income (expense) 14.54M014.54M
Special income (charges) --0--14.54M--0--0--0--14.54M--0--0--0--0
-Gain on sale of business --0--14.54M--0--0--0--14.54M--0--0--0--0
Income before tax -30.62%-132.97M-191.13%-422.71M3.98%-114.69M-7.89%-107.19M-154.00%-99.03M7.27%-101.8M55.46%-145.19M-21.04%-119.44M3.82%-99.35M412.05%183.38M
Income tax 126.67%68K42.86%30K
Net income -30.62%-132.97M-191.12%-422.77M3.95%-114.75M-7.89%-107.19M-154.00%-99.03M7.27%-101.8M55.45%-145.22M-21.07%-119.47M3.82%-99.35M411.91%183.38M
Net income continuous Operations -30.62%-132.97M-191.12%-422.77M3.95%-114.75M-7.89%-107.19M-154.00%-99.03M7.27%-101.8M55.45%-145.22M-21.07%-119.47M3.82%-99.35M411.91%183.38M
Minority interest income
Net income attributable to the parent company -30.62%-132.97M-191.12%-422.77M3.95%-114.75M-7.89%-107.19M-154.00%-99.03M7.27%-101.8M55.45%-145.22M-21.07%-119.47M3.82%-99.35M411.91%183.38M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -30.62%-132.97M-191.12%-422.77M3.95%-114.75M-7.89%-107.19M-154.00%-99.03M7.27%-101.8M55.45%-145.22M-21.07%-119.47M3.82%-99.35M411.91%183.38M
Basic earnings per share -14.71%-0.78-142.45%-2.5722.09%-0.6712.50%-0.63-144.03%-0.5915.00%-0.6859.23%-1.06-14.67%-0.8614.29%-0.72379.17%1.34
Diluted earnings per share -14.71%-0.78-142.45%-2.5722.09%-0.6712.50%-0.63-145.38%-0.5915.00%-0.6859.23%-1.06-14.67%-0.8614.29%-0.72370.83%1.3
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions --Unqualified Opinion--------Unqualified Opinion------

Market Insights

Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

No. Symbol Price
YETI Holdings
YETI
32.160
Halozyme Therapeutics
HALO
48.950
eBay
EBAY
70.600
4
Constellation Brands
STZ
190.650
5
Workday
WDAY
274.710
Log In for the Full List
Unlock Now

Investment Course

Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.

Discussing

Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
MicroStrategy Q4 2024 earnings conference call

Monetary Policy: Navigating the Fed's Rate Cut Cycle

Changing Fed policy is altering the market math for investors.